Fig. 4: Randomised comparison of non-breast cancer mortality showing signifcantly fewer deaths in patients randomised to TARGIT-IORT(top graph), and non-randomised comparisons to assess the contribution to the difference seen in the randomised comparison: because of the delivery of TARGIT-IORT (bottom left), and the avoidance of EBRT (bottom right). | British Journal of Cancer

Fig. 4: Randomised comparison of non-breast cancer mortality showing signifcantly fewer deaths in patients randomised to TARGIT-IORT(top graph), and non-randomised comparisons to assess the contribution to the difference seen in the randomised comparison: because of the delivery of TARGIT-IORT (bottom left), and the avoidance of EBRT (bottom right).

From: New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer

Fig. 4

Please note that 40% of patients in the 1158 EBRT arm also received a tumour-bed boost which was not given to those who had received TARGIT-IORT.

Back to article page